Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent developments in the prosecution of the CRISPR-Cas9 patent in Europe highlight the differences between the intellectual property regimes of Europe and the United States.
A survey of the claims of antibody-related patents granted by the European Patent Office and a review of the type and scope of product claims granted for antibodies.
The unprecedented weakening of patent rights in the United States undermines necessary incentives for the discovery and development of innovative medicines.
Will freedom to research and innovate be restricted as the induced pluripotent stem cell field advances toward the clinic, or are concerns premature within a rapidly changing ecosystem?
The rate of invention may be a valuable metric for identifying strategic R&D investments to enhance knowledge creation, translational value and economic potential from NIH-supported research.
CRISPR-Cas systems, which enable the production of new artificial genes, synthetic proteins and new transgenic organisms, will challenge patent practices worldwide.